Goals and Objectives:
- To expedite the development and validation processes for new anticancer and cancer prevention agents.
- To educate investigators, so new agents may be made available to patients at a more efficient rate more rapidly in the future.
- To improve understanding of cancer drug development strategies to lead to a series of pivotal clinical trials demonstrating efficacy and patient benefit.
Who Should Attend:
- Industry: Registrants should be involved in drug development.
- Government: Registrants should be employed by an U.S. government agency and be involved in oncology drug discovery or development.
- Academic: Registrants should be employed by a recognized academic institution and be involved or have an interest in oncology drug discovery and/or development. Previous or current experience in the conduct of clinical trials is helpful, but not required.
- Advocates: Consumer and/or patient advocates should be sponsored by a nationally recognized advocacy organization or foundation. Advocates should have a background in clinical trial design and the role of the advocate in the development process.
If to Duke:
- Mary Ruemker
DUMC Box 2606
Durham, North Carolina 27710
If to FDA:
- Jura Viesulas, MS, EdD
Office of Hematology and Oncology Products
Bldg. 22 Room 2200
10903 New Hampshire Avenue
Food and Drug Administration
Silver Spring, MD 20993